Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.

Introduction

Multiple myeloma (MM) is an incurable plasma cell malignancy of the bone marrow, characterized by multiple relapses and eventual development of resistant disease. The duration of treatment response typically reduces with each line of therapy, as does the depth of response. A large retrospective study of European real-world data demonstrated that the proportion of patients able to receive treatment reduces with each subsequent line of treatment, with only 15% of patients reaching 4 th line treatment and beyond ( 1 ). This is likely due to resistant disease, toxicity burden from repeated therapies and age-related co-morbidities. However, recent novel therapy approvals and the development of more optimal drug combinations have translated into improved clinical outcomes, with an expected increase in number of patients receiving later lines of therapy.

Lenalidomide, an immunomodulatory drug (IMiD), is a key backbone agent in the treatment of MM and commonly used as frontline treatment for both transplant eligible and ineligible patients either in combination with proteasome inhibitors (PI), alkylators and/or CD38 monoclonal antibodies or as a doublet with corticosteroids according to performance status ( 2 , 3 ). Additionally, it is used as maintenance following autologous stem cell transplant ( 4 , 5 ). In some countries including the U.K., it continues to be used for relapsed MM ( 6 – 9 ) [ Supplementary Figure 1 , ( 10 – 13 )].

As lenalidomide is typically continued until disease progression or intolerance, most patients become lenalidomide-refractory. Emerging data from sub-group analysis of clinical trials suggest that the treatment response and progression free survival (PFS) of lenalidomide-refractory patients are inferior to those that are sensitive ( 14 – 20 ). Real-world data from RRMM patients who were refractory to an IMiD also demonstrated poor outcomes [ Supplementary Figure 2 , ( 21 – 23 )]. This highlights a subgroup of patients who are difficult to treat and the need for novel treatment options.

However, there may be discrepancies between clinical trial and real-world outcomes due to multiple patient-related, disease-related and treatment-related factors present between the two groups ( 24 ). The observed PFS in real-world data have been shown to be shorter than those reported in clinical trials ( 25 ), although there is a lack of clarity to the subsequent responses to treatments. Real-world data can be helpful in identifying outcomes in unselected patient groups, indeed the Connect MM registry suggested that 40% of patients would have been ineligible for inclusion in most randomized controlled trials ( 26 ). Whilst there are limitations in real-world datasets ( 27 ), they provide valuable insight into the natural history of patients that would otherwise not be known through individual clinical trials.

We therefore sought to understand the long-term outcomes of patients with relapsed or refractory MM (RRMM) following lenalidomide failure in the real-world setting by characterizing the response and PFS to each subsequent treatment and investigating the impact of access to novel agents through clinical trials.

Materials and Methods

Study Design and Patient Selection

This was a retrospective, observational chart review study involving two large U.K. myeloma specialist centers (University College London Hospitals NHS Foundation Trust (UCLH) and Leeds Teaching Hospitals NHS Trust). RRMM patients who had previously received lenalidomide between August 2006 and September 2017 were identified using the hospitals’ electronic health record systems. Patients were required to have at least one response assessment with a lenalidomide-based regimen in order to be included in the study. Baseline demographic details, disease characteristics and relevant laboratory blood results were recorded. International Staging System (ISS) at diagnosis and Eastern Cooperative Oncology Group (ECOG) performance status at the time of lenalidomide use were noted. Lenalidomide-based treatment was defined as T0 and subsequent treatments were labelled as T1, T2, T3 etc. Treatment details were extracted, including clinical trial participation and treatment response based on the International Myeloma Working Group (IMWG) uniform response criteria ( 28 ).

The National Health Service Health Research Authority deemed that specific research ethical approval was not required due to the anonymous nature of the data collection (REF 704/60/88/81), and this study complied with information governance regulations at both hospitals.

Study Objectives

The primary objective was to estimate the duration of PFS at each subsequent line of therapy after lenalidomide-based treatment. Secondary objectives included describing overall response rate [ORR, defined as ≥ partial response (PR)] and response categories, overall survival (OS), and outcomes according to participation in clinical trials.

Statistical Analysis

Qualitative variables were presented as absolute percentage for each modality and quantitative variables were described in terms of mean, median, range and standard deviation. OS was measured from treatment start until death from any cause. PFS was measured from treatment start until whichever came first of disease progression or death from any cause. Patients with no events were censored at the data-cut off of 1 st November 2017. OS and PFS were calculated and presented as Kaplan-Meier curves. Differences in OS curves between groups were evaluated with the log-rank test. Cox regression analysis was used to examine the impact of different variables (univariate and multivariate) on OS post-lenalidomide. A p-value less than 0.05 was considered statistically significant. SPSS Statistics and GraphPad Prism were used to generate figures.

Results

Patient Characteristics

198 RRMM patients were identified to have commenced lenalidomide-based treatment between August 2006 and September 2017 and had at least one evaluable response assessment. Of these, 159 were treated in UCLH and 39 in Leeds Teaching Hospitals NHS Trust. Patient demographics are shown in Table 1 .

Outcomes With Lenalidomide and Overall Survival

The median age at the start of lenalidomide based therapy (T0) was 66 years (range 35-88). Patients received a median of 2 prior treatment lines before T0 (18%: 1 prior line, 82%: 2-3 prior lines). The majority of patients (n=146, 74%) received both a PI and thalidomide prior to lenalidomide therapy. Patients commenced lenalidomide at a median of 41 months from diagnosis (range 0.5-210), predominantly as doublet lenalidomide-dexamethasone regimen (n=138, 86% of 159 evaluable). Other regimens used include bortezomib-lenalidomide-dexamethasone (n=6, 4%), ixazomib-lenalidomide-dexamethasone (n=6, 4%), lenalidomide-dexamethasone-elotuzumab (n=2, 1.5%), daratumumab-lenalidomide-dexamethasone (n=5, 3%), cyclophosphamide-lenalidomide-dexamethasone (n=1, 0.6%), and lenalidomide-conditioned reduced intensity allogeneic stem cell transplant (n=1, 0.6%). Lenalidomide doses at disease progression were available in 98 patients ( Supplementary Figure 3A ).

The overall response rate to lenalidomide-based treatment was 67% (n=133) ( Figure 1A ): PR, 66 (33%); very good partial response (VGPR), 58 (29%); complete response (CR), 9(5%). The median PFS from T0 was 11.1 months (range 0.2-93.4) ( Figure 1B ) and median OS was 28.4 months with a median follow up of 33.8 months ( Figure 2A ). The median OS from IMWG defined disease progression on lenalidomide or change of therapy for another reason was 14.7 months. The median OS from T1 was 11.6 months as shown in Figure 2B . Those who achieved a response to lenalidomide had a superior OS than those who did not (38.6 months with VGPR/PR versus 12.3 months with MR/SD/PD, p<0.0001, see Supplementary Figure 6A ). Those who became refractory to lenalidomide also had a shorter OS than those who did not (median OS 26.2 months versus not reached, p<0.0001, see Supplementary Figure 6B ). In an exploratory analysis of the sub-group that had doses of lenalidomide recorded, there was no significant difference in PFS2 or OS for those progressing on lenalidomide 25mg vs <25mg (PFS2: 16 months vs 28.4 months respectively p=0.24; OS: 36.7months vs 22.0 months respectively p=0.055) ( Supplementary Figure 3B ).

As of data cut-off, 41 patients had not progressed on lenalidomide, of whom 31 were still alive and 10 had died. Lenalidomide was stopped due to toxicity in 11 (7%) patients. The majority of patients (n=112, 71% of 158 evaluable) became refractory to lenalidomide after an initial response. Despite this, 81 (51%) continued on lenalidomide for a median of 4.14 months (range 0.1-31.5) after evidence of progressive disease (PD). Out of these 81 patients, 24 continued on lenalidomide for more than 6 months. Overall, 31 (15.7% of 198 total population) patients progressed on lenalidomide and died without receiving any further treatment.

Subsequent Lines of Therapy Post-Lenalidomide

The absolute numbers of patients that were able to receive treatment diminished at each subsequent line after lenalidomide ( Figure 3A ): 113 patients (57%) received the next line of treatment after lenalidomide (T1), 61 (31%) received a further line (T2), 24 (12%) reached the subsequent line (T3) and 10 (5%) reached T4. Only two patients remained on treatment at T5 and beyond. The drop in patients able to receive subsequent lines of treatment was predominantly due to deaths during that line of treatment ( Figure 3B ). A smaller number had either PD but not yet changed treatment, or had not yet progressed. Approximately a third of subjects died at each line from T1 to T3.

A variety of other treatments were used immediately after lenalidomide. The most common was a pomalidomide containing regimen, although some were enrolled in clinical trials, or received alternative treatments including low dose palliative chemotherapy (for full list, see Supplementary Figure 4 ).

The overall and depth of response was limited at sequential lines of treatment ( Figure 1A and Supplementary Figure 5 ). Overall response rates (≥PR) were as follows: T1 - 32% (36/113); T2 - 26% (16/61); T3 - 50% (12/24); T4 - 20% (2/10); T5 - 50% (1/2); T6 - 0% (0/1). Most patients achieved at least stable disease; deeper responses (≥VGPR) were rarely observed. The median PFS for each subsequent treatment was also short at 5.7 months at T1, 6.6 months at T2, 6.7 months at T3 and 3.6 months at T4 ( Figure 1B ).

As the majority (112/158, 71%) of patients were refractory to lenalidomide at the beginning of the next treatment (T1), PFS2 [from commencing lenalidomide to progression on next line of therapy (T1)] was assessed to review if there was an optimal salvage treatment for such patients, taking into consideration the duration of response to lenalidomide. The median PFS2 was similar irrespective of treatment choice (pomalidomide (n=28): 23 months, bortezomib and Panobinostat (n=12): 24 months, bendamustine (n=16): 25 months, with clinical trials (n=9): 19 months, other therapies (n=48): 25 months (p=0.89 (log rank)) ( Figure 4 ). For those who received pomalidomide at T1, the PFS was significantly longer in those who achieved a longer (over 6 months) PFS with lenalidomide (7.04 months versus 2.78 months, p=0.038, see Supplementary Figure 7 ).

Clinical Trial Participation and Overall Survival

Overall, 37 patients (33%) enrolled in a clinical trial at any time after lenalidomide-based treatment. These patients had a superior median OS from T1 to those that did not (30.0 months versus 8.8 months, p=0.0002; HR 2.41, 95% CI 1.53 - 3.80, Figure 5 ). However, a high early mortality was noted in the non-trial group with a 6-month mortality of 91.9% (non-trial) versus 63.2% (trial) (p=0.0017, HR 3.2, 95% CI 1.5-6.7) from commencing T1. In univariate analysis of OS, C-reactive protein (CRP), platelet or neutrophil count, estimated glomerular filtration rate (eGFR, MDRD), high risk cytogenetics or patient age had no impact. However, subsequent trial enrollment, good performance status (ECOG 0-1), higher hemoglobin and higher albumin were all associated with significantly better overall survival. Significance was maintained in a multivariable model of these 4 variables, however some were excluded from this model as they did not have complete data ( Figure 6 ).

Discussion

The current treatment paradigm for MM involves continuous treatment until disease progression. Therefore, patients become refractory to treatments, which subsequently limit further options. Many patients become refractory to lenalidomide early on in their treatment pathway and this group have inferior outcomes compared to those who are not, as demonstrated in published studies as well as our dataset. Additionally, during the current COVID-19 pandemic some patients would have deferred ASCT and are continuing on lenalidomide instead. Understanding the natural history of patients following lenalidomide in the real world can therefore advise optimal management and help design future trials.

This study demonstrated that the survival after failing lenalidomide at 3 rd line for relapsed MM was poor at 14.7 months, with fewer patients able to receive subsequent lines. Due to limited available data, a difference in outcomes for those progressing on full treatment dose lenalidomide versus a lower dose was not noted. This remains an area of interest. Subsequent response rates following lenalidomide were low with very few deep responses (≥VGPR) observed. Additionally, the median PFS for each subsequent line was less than 7 months and more patients died at each subsequent line. These observations suggest that patients should be treated with optimal treatment as early as possible, rather than reserving treatments for later lines, as not all patients will live to reach this point. As treatment advances continue, new and effective treatments are under evaluation. The advent of B-cell maturation antigen (BCMA) targeted treatments such as Belantamab Mafodotin, chimeric antigen reception T-cells (CAR-T) and T-cell engagers as well as the incorporation of antibodies with standard to care regimens will lead to more effective salvage regimens for relapsed patients. Indeed, the ORR and durations of response to these treatments are already demonstrating improvements over historical data ( 29 ). However, these agents are not all yet routinely available and when they are licensed, they may be restricted in some countries. Therefore, it was of interest that patients enrolled into clinical trials had an improved survival to those that did not. This may be in part due to the effectiveness of the novel treatments; however, the early mortality of the non-trial patients as well as the difference in parameters such as hemoglobin and albumin suggests that the clinical trial group was potentially a biologically fitter group which is not surprising given the selection criteria for trials. Nevertheless, this data supports enrollment of patients into clinical trials to access novel treatments, although the impact could be greater if eligibility criteria were not so strict.

It is of interest that some patients continued on treatment with lenalidomide for over 6 months after IMWG defined disease progression due to lack of clinical relapse. This is relevant for treatment funders that may assume that treatments are stopped at the time of IMWG defined progression. Indeed, the clonal heterogeneity and patient variability observed in MM requires personalized decisions to be made based on the clinical phenotype of disease, genetic risk and patient preference, and as such some patients with indolent relapses continued on treatment for longer. There was no difference in PFS2 according to immediate next treatment, and so this dataset was unable to recommend an optimal treatment for lenalidomide-refractory patients, although those that had a PFS < 6 months had a shorter PFS with pomalidomide and should be considered for a class switch to a proteasome inhibitor-based combination. Ongoing clinical trials will be critical to guide this.

This study is limited by its retrospective nature, the heterogeneity of the lenalidomide-refractory cohort who received lenalidomide in line 1 to 3, and that newer agents and combination regimens have been approved or made available since the beginning of data collection in 2006. In addition, this data focuses on the use of lenalidomide in the relapsed setting whereas today it can be used at first line. However, this historical data allows longer follow-up and the ability to describe longitudinal outcomes according to each subsequent line. It also provides interesting data describing that natural plight of MM patients that switch from treatment to treatment across multiple lines at relapse.

Of note, one large U.S. real-world multi-sites myeloma dataset where 23.8% of patients were treated with lenalidomide upfront demonstrated a median PFS of 11.5 months ( 25 ), similar to our median lenalidomide PFS of 11.1 months. Furthermore, lenalidomide remains a treatment option only in relapsed settings for some countries across the world. Another limitation is that the number of patients in later lines of treatment are small, but this represents the eventual incurable nature of the disease despite multiple lines of treatment. Further research examining quality of life in the real world would be of interest for these patients.

In conclusion, these data provide valuable insights into the real-world outcomes of patients with relapsed refractory MM that have failed lenalidomide and highlights an unmet need for the development of more effective treatment strategies.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the corresponding author upon reasonable request, without undue reservation.

Author Contributions

CL and JT are joint first authors. CL, JT, KY, GC, and RP designed the study. CP, GW, CK, LL, SM, XP, NR, JS, AW, KY, GC, and RP provided data. CL, JT, and JC collected the data. CL, JT, and WW analyzed the data. CL, JT, and RP wrote the paper. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

RP is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. GC and JC are funded by the National Institute for Health Research Leeds In Vitro Diagnostics Co-operative. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.703233/full#supplementary-material

Click here for additional data file.

References

1 Yong K Delforge M Driessen C Fink L Flinois A Gonzalez-McQuire S . Multiple Myeloma: Patient Outcomes in Real-World Practice . Br J Haematol ( 2016 ) 175 ( 2 ): 252–64 . 10.1111/bjh.14213 PMC5096152 27411022

2 Benboubker L Dimopoulos MA Dispenzieri A Catalano J Belch AR Cavo M . Lenalidomide and Dexamethasone in Transplant-Ineligible Patients With Myeloma . N Engl J Med ( 2014 ) 371 ( 10 ): 906–17 . 10.1056/NEJMoa1402551 25184863

3 Durie BGM Hoering A Abidi MH Rajkumar SV Epstein J Kahanic SP . Bortezomib With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients With Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial . Lancet ( 2017 ) 389 ( 10068 ): 519–27 . 10.1016/S0140-6736(16)31594-X PMC5546834 28017406

4 McCarthy PL Holstein SA Petrucci MT Richardson PG Hulin C Tosi P . Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis . J Clin Oncol ( 2017 ) 35 ( 29 ): 3279–89 . 10.1200/JCO.2017.72.6679 PMC5652871 28742454

5 Jackson GH Davies FE Pawlyn C Cairns DA Striha A Collett C . Lenalidomide Maintenance Versus Observation for Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial . Lancet Oncol ( 2019 ) 20 ( 1 ): 57 – 73 . 10.1016/S1470-2045(18)30687-9 30559051 PMC6318225

6 Moreau P Masszi T Grzasko N Bahlis NJ Hansson M Pour L . Oral Ixazomib, Lenalidomide, and Dexamethazone for Multiple Myeloma . N Engl J Med ( 2016 ) 374 ( 17 ): 1621–34 . 10.1056/NEJMoa1516282 27119237

7 Dimopoulos MA Oriol A Nahi H San-Miguel J Bahlis NJ Usmani SZ . Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma . N Engl J Med ( 2016 ) 375 ( 14 ): 1319–31 . 10.1056/NEJMoa1607751 27705267

8 Morgan GJ Schey SA Wu P Srikanth M Phekoo KJ Jenner M . Lenalidomide (Revlimid), in Combination With Cyclophosphamide and Dexamethasone (RCD), Is an Effective and Tolerated Regimen for Myeloma Patients . Br J Haematol ( 2007 ) 137 ( 3 ): 268–9 . 10.1111/j.1365-2141.2007.06538.x 17408469

9 Stewart AK Rajkumar SV Dimopoulos MA Masszi T Špička I Oriol A . Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma . N Engl J Med ( 2015 ) 372 ( 2 ): 142–52 . 10.1056/NEJMoa1411321 25482145

10 Siegel DS Dimopoulos MA Ludwig H Facon T Goldschmidt H Jakubowiak A . Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma . J Clin Oncol ( 2018 ) 36 ( 8 ): 728–34 . 10.1200/JCO.2017.76.5032 29341834

11 Lonial S Dimopoulos M Palumbo A White D Grosicki S Spicka I . Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma . N Engl J Med ( 2015 ) 373 ( 7 ): 621–31 . 10.1056/NEJMoa1505654 26035255

12 Dimopoulos M Lonial S White D Moreau P Weisel K San-Miguel J . Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results From the Phase 3 Randomized ELOQUENT-2 Study . Blood Cancer J ( 2020 ) 10 ( 9 ): 91 . 10.1038/s41408-020-00357-4 32887873 PMC7474076

13 Richardson PG Kumar SK Masszi T Grzasko N Bahlis NJ Hansson M . Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma . J Clin Oncol ( 2021 ) JCO2100972 . 10.1200/JCO.21.00972 34111952

14 Richardson PG Oriol A Beksac M Liberati AM Galli M Schjesvold F . Pomalidomide, Bortezomib, and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial . Lancet Oncol ( 2019 ) 20 ( 6 ): 781–94 . 10.1016/S1470-2045(19)30152-4 31097405

15 Dimopoulos MA Terpos E Baccadoro M Delimpasi S Beksac M Katodritou E . APOLLO: Phase 3 Randomised Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone Versus Pomalidomide and Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma , in: . Available at: https://ash.confex.com/ash/2020/webprogram/Paper135874.html (Accessed February 23, 2021 ).

16 Dimopoulos MA Moreau P Palumbo A Joshua D Pour L Hájek R . Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study . Lancet Oncol ( 2016 ) 17 ( 1 ): 27 – 38 . 10.1016/S1470-2045(15)00464-7 26671818

17 Palumbo A Chanan-Khan A Weisel K Nooka AK Masszi T Beksac M . Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma . N Engl J Med ( 2016 ) 375 ( 8 ): 754–66 . 10.1056/NEJMoa1606038 27557302

18 Dimopoulos MA Dytfeld D Grosicki S Moreau P Takezako N Hori M . Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma . N Engl J Med ( 2018 ) 379 ( 19 ): 1811–22 . 10.1056/NEJMoa1805762 30403938

19 Dimopoulos M Quach H Mateos MV Landgren O Leleu X Siegel D . Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (CANDOR): Results From a Randomised, Multicentre, Open-Label, Phase 3 Study . Lancet ( 2020 ) 396 ( 10245 ): 186–97 . 10.1016/S0140-6736(20)30734-0 32682484

20 Attal M Richardson PG Rajkumar SV San-Miguel J Beksac M Spicka I . Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study . Lancet ( 2019 ) 394 ( 10214 ): 2096–107 . 10.1097/01.HS9.0000561576.58696.ae 31735560

21 Kumar SK Lee JH Lahuerta JJ Morgan G Richardson PG Crowley J . Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy With IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study . Leukaemia ( 2012 ) 26 ( 1 ): 149–57 . 10.1038/leu.2011.196 PMC4109061 21799510

22 Kumar SK Dimopoulos MA Kastritis E Terpos E Nahi H Goldschmidt H . Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study . Leukaemia ( 2017 ) 31 ( 11 ): 2443–8 . 10.1038/leu.2017.138 28620163

23 Usmani S Ahmadi T Ng Y Lam A Desai A Potluri R . Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With >3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD . Oncologist ( 2016 ) 21 ( 11 ): 1355–61 . 10.1634/theoncologist.2016-0104 PMC5189616 27486203

24 Richardson PG San Miguel JF Moreau P Hajek R Dimopoulos MA Laubach JP . Interpreting Clinical Trial Data in Multiple Myeloma: Translating Findings to the Real-World Setting . Blood Cancer J ( 2018 ) 8 ( 11 ): 109 . 10.1038/s41408-018-0141-0 30413684 PMC6226527

25 Jagannath S Roy A Kish J Lunacsek O Globe D Eaddy M . Real-World Treatment Patterns and Associated Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Among US Community Oncology Practices . Expert Rev Hematol ( 2016 ) 9 ( 7 ): 707–17 . 10.1080/17474086.2016.1195254 27291638

26 Shah JJ Abonour R Gasparetto C Hardin JW Toomey K Narang M . Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes . Clin Lymphoma Myeloma Leuk ( 2017 ) 17 ( 9 ): 575–83 . 10.1016/j.clml.2017.06.013 28886839

27 Collins R Bowman L Landray M Peto R . The Magic of Randomization Versus the Myth of Real-World Evidence . N Engl J Med ( 2020 ) 382 ( 7 ): 674–8 . 10.1056/NEJMsb1901642 32053307

28 Kumar S Paiva B Anderson KC Durie B Landgren O Moreau P . International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma . Lancet Oncol ( 2016 ) 17 ( 8 ): e328–46 . 10.1016/S1470-2045(16)30206-6 27511158

29 Yu B Jiang T Liu D . BCMA-Targeted Immunotherapy for Multiple Myeloma . J Hematol Oncol ( 2020 ) 13 : 125 . 10.1186/s13045-020-00962-7 32943087 PMC7499842